Given that only ~20% of patients with AL amyloidosis may be able to undergo ASCT and the widespread use of anti-CD38 antibodies [41], we explored the prognostic value of Holter monitoring for OS in a cohort that mainly included non-transplant patients, among which 23.4% received daratumumab-based therapy and drew different conclusions than other studies. The gene discussed is CD38; the disease is AL amyloidosis.